Home » Topics » BioWorld Science, Respiratory

BioWorld Science, Respiratory
RSS

AI-driven discovery of novel candidates for idiopathic pulmonary fibrosis

Sep. 7, 2021

BI-1265162, an inhaled ENaC inhibitor for the mutation-agnostic treatment of cystic fibrosis

Sep. 6, 2021

HEC-866, a novel pirfenidone analogue with improved therapeutic efficacy in models of IPF

Sep. 6, 2021

Galectin-3 inhibition by tetrahydropyran-based thiodisaccharide mimics

Sep. 2, 2021

Study may lead to new pulmonary fibrosis treatments

Aug. 30, 2021

Blade receives IND clearance for phase I study of cudetaxestat for IPF

Aug. 26, 2021

JadiCells show promise in animal model of COPD

Aug. 24, 2021

Phase I data reported for GDC-3280 in healthy subjects

Aug. 23, 2021

Kaleido and COPD Foundation collaborate to advance development of KB-109

Aug. 11, 2021

aTyr expands its research collaboration with Ohio State University

Aug. 11, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...